论文部分内容阅读
本文介绍了试用白细胞粘附抑制验试(Leucocyteadberence inhibition test)来诊断肝癌。试验对象包括肝细胞癌6例,肝母细胞瘤1例,继发性肝肿瘤3例(分别为恶性黑色素瘤、肺的腺癌、子宫颈鳞癌),肝病43例(其中肝硬变33例),未侵犯肝脏的其它癌肿4例(黑色素瘤和乳腺、结肠、胃的腺癌)。验试原理:当癌症患者的白细胞与相应肿瘤抗原混合后,白细胞与玻片粘附的倾向即被抑制,而这些患者的血清又能干扰或“阻断”这种抑制作用。
This article describes the use of Leucocyteadberence inhibition test to diagnose liver cancer. The test subjects included six cases of hepatocellular carcinoma, one case of hepatoblastoma, three cases of secondary hepatic neoplasms (malignant melanoma, adenocarcinoma of the lung, squamous cell carcinoma of the cervix), and 43 cases of hepatopathy (including cirrhosis of the liver). Example) Four other cancers that did not invade the liver (melanoma and adenocarcinoma of the breast, colon, and stomach). Test principle: When cancer patients’ leukocytes are mixed with the corresponding tumor antigens, the tendency of white blood cells to adhere to the slides is inhibited, and the serum of these patients can interfere with or “block” this inhibitory effect.